Please login to the form below

ledipasvir

This page shows the latest ledipasvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie sues NHS England over hep C procurement

treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective against all HCV genotypes.

Latest news

Gilead wins European approval for triple hep C combination Vosevi

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include
Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half
Gilead makes $11.9bn play for CAR-T specialist Kite

Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call
Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
Samsung Bioepis wins CHMP nod for second Humira biosimilar

Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and

More from news
Approximately 4 fully matching, plus 63 partially matching documents found.

Latest Intelligence

AbbVie: New firm, new thinking

Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Account Director, Medical Education: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Senior Medical Writer: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer: Competitive salary and benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Director – Healthcare PR: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Subscribe to our email news alerts

PMHub

Add my company

Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...